Share this page
Print this page
Email alert
ASTHMA AND COPD
Targeting the PI3K Delta is a novel approach for the treatment of inflammatory disorders such as asthma, chronic obstructive pulmonary disease and rheumatoid arthritis.
Asthma and COPD
In preclinical models of asthma and COPD, inhibition of PI3K Delta reduces Th2 cytokines, diminishing airway inflammation, attenuation of leukocyte activation, and airway hyper-responsiveness.
Through direct effects on mast cells, inhibition of PI3K Delta results in deceases in histamines, leukotrienes, and prostaglandin D2.
Additionally through a direct effect on B cells, IgE production is decreased.